Sustainability
Two lawyers within EU legal chamber Axon Lawyers created a Green Team to cope with the rise in EU Green Deal and related environmental sustainability and compliance needs for medtechs. One of them, Jilles van der Hoek, explains why manufacturers should be getting a jump on future requirements.
The latest annual UK ABHI survey of medtech industry sentiment on market access, regulatory hurdles and pathways for innovation reveals polarized views and levels of frustration among manufacturers who face ever higher compliance workloads.
Pharmaceutical companies are already adapting their existing processes to align with and implement a new global standard for evaluating the environmental impact of pharmaceutical products.
A program to help healthtech innovators comply with NHS sustainability targets without compromising their unique R&D propositions has been launched by the UK government’s healthcare research arm and the Pd-m consultancy.
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
A new European initiative will help trial sponsors better understand whether digitization and decentralized clinical trials of drugs generate less carbon than traditional methods.
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.
As deadlines approach, the regulatory landscape for medtech batteries is set to change, with an emphasis on sustainability and ethical practices.
A new methodology for measuring pharmaceutical company carbon footprints could lead to a single standard for producing these calculations that is applicable to all medicines sold in France, said the industry association, Leem. However, it warned that there remains uncertainty about how the methodology will work in practice.
Restrictions on commonly used chemicals, increased reporting requirements and enhanced environmental risk assessments are just some of the new EU sustainability and environmental rules pharmaceutical companies are potentially facing. While some measures are multi-sectoral, others are pharma specific. The Pink Sheet takes a look at some of the developments in 2024 and expectations for 2025 and beyond.
The World Health Organization (WHO) has launched an initiative to highlight the pressing global need to reduce the impact of the pharmaceutical industry on the environment while maintaining high standards of safety and efficacy for products.